CompletedPhase 2NCT04243122
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ottawa Hospital Research Institute
- Principal Investigator
- Aurelien Delluc, MD, PhDThe Ottawa Hospital
- Intervention
- Apixaban 2.5 MG Oral Tablet [ELIQUIS](drug)
- Enrollment
- 44 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- The Ottawa Hospital, Ottawa, Ontario, Canada
Collaborators
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network · the Association médicale universitaire de l'Hôpital Montfort (AMUHM) · Canadian Hematology Society
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04243122 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07340138Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07357727A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.